Cross-source identity
National Provider Identifier 1881339182 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|---|---|---|
| CMS Open Payments |
| NPI 1881339182 |
| 38 industry-payment records, 2024 |
| Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1881339182 | 30 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity cd187171… | Canonical resolved node · 2 identifier(s) · 13 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $944 | 38 |
| Manufacturer | Amount | Records |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $230 | 8 |
| Axsome Therapeutics, Inc. | $158 | 3 |
| Neurocrine Biosciences, Inc. | $140 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Austedo Xr(Deutetrabenazine) | 63 | $669,598 |
| Spravato(Esketamine Hcl) | 11 | $51,770 |
| Dayvigo(Lemborexant) | 70 | $30,799 |
| Lybalvi(Olanzapine/Samidorphan Malate) | 13 | $30,741 |
| Trintellix(Vortioxetine Hydrobromide) | 24 | $19,229 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Noven Therapeutics, Llc (FL) | cms_open_payments |
| ← pays | Corium, Llc (MA) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Otsuka America Pharmaceutical, Inc. (MD) | cms_open_payments |
| ← pays | Lilly Usa, Llc (IN) | cms_open_payments |
| ← pays | Takeda Pharmaceuticals U.S.A., Inc. (MA) | cms_open_payments |
| ← pays | Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) (NJ) | cms_open_payments |
| ← pays | Lundbeck Llc (IL) | cms_open_payments |
| ← pays | Supernus Pharmaceuticals, Inc. (MD) | cms_open_payments |
| ← pays | Axsome Therapeutics, Inc. (NY) | cms_open_payments |
| ← pays | Neurocrine Biosciences, Inc. (CA) | cms_open_payments |
| ← pays | Teva Pharmaceuticals Usa, Inc. (NJ) | cms_open_payments |
| 6 |
| Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) | $73 | 4 |
| Teva Pharmaceuticals Usa, Inc. | $60 | 3 |